Adiso Therapeutics
Adiso Therapeutics is a clinical-stage biotechnology company dedicated to creating medicines to treat inflammatory diseases, aiming to improve patients' lives through innovative, first-in-class therapies with novel mechanisms of action. The company focuses on targeted treatments for conditions like ulcerative colitis, neuroinflammation, and respiratory inflammation, leveraging a pipeline of small molecules and live biotherapeutic products. Guided by values of innovation and patient impact, Adiso collaborates with academic and institutional partners to advance its mission.
Industries
Nr. of Employees
small (1-50)
Adiso Therapeutics
530 Virginia Road, Suite 300, Concord, MA 01742
Patents
Products
ADS051
Orally administered, gut-restricted small molecule designed to modulate neutrophil trafficking into and activation within the intestinal lumen for the treatment of ulcerative colitis; evaluated in SAD and MAD/Phase 1b studies with limited systemic exposure reported.
ADS032
Novel small molecule program that inhibits two inflammasome pathways (NLRP1 and NLRP3) for development in respiratory and dermal inflammatory diseases; supported by preclinical data and scientific posters/publications.
ADS024
Oral single-strain live biotherapeutic product developed from a clonal bacterial cell bank as a lyophilized drug product, being evaluated for treatment of mild-to-moderate ulcerative colitis and prevention of C. difficile recurrence; supported by preclinical efficacy data in multiple animal models.
ADS051
Orally administered, gut-restricted small molecule designed to modulate neutrophil trafficking into and activation within the intestinal lumen for the treatment of ulcerative colitis; evaluated in SAD and MAD/Phase 1b studies with limited systemic exposure reported.
ADS032
Novel small molecule program that inhibits two inflammasome pathways (NLRP1 and NLRP3) for development in respiratory and dermal inflammatory diseases; supported by preclinical data and scientific posters/publications.
ADS024
Oral single-strain live biotherapeutic product developed from a clonal bacterial cell bank as a lyophilized drug product, being evaluated for treatment of mild-to-moderate ulcerative colitis and prevention of C. difficile recurrence; supported by preclinical efficacy data in multiple animal models.
Services
Engagement with investors and strategic partners for collaboration on specific development programs, sharing program data and IP to support licensing or co-development.
Point of contact and information resource for inquiries about active clinical trials and enrollment; guidance to clinicaltrials.gov listings.
Engagement with investors and strategic partners for collaboration on specific development programs, sharing program data and IP to support licensing or co-development.
Point of contact and information resource for inquiries about active clinical trials and enrollment; guidance to clinicaltrials.gov listings.
Expertise Areas
- Clinical trial management (early-phase SAD/MAD/Phase 1b/Phase 2)
- Small molecule drug discovery and preclinical development
- Live biotherapeutic product (SS-LBP) development and manufacturing
- Inflammasome-targeted therapeutics development
Key Technologies
- Small molecule inhibitor discovery
- Dual-target inflammasome inhibition (NLRP1/NLRP3)
- Modulation of neutrophil trafficking and activation
- Single-strain live biotherapeutic (SS-LBP) platform
News & Updates
A press release announcing the publication of data from two Phase 1 studies of ADS051, a neutrophil modulator for ulcerative colitis.
A publication detailing the safety and tolerability of ADS051 in a Phase 1 study.
A study reporting on the safety, pharmacokinetics, and efficacy of ADS051 in ulcerative colitis.
A press release announcing the publication of data from two Phase 1 studies of ADS051, a neutrophil modulator for ulcerative colitis.
A publication detailing the safety and tolerability of ADS051 in a Phase 1 study.
A study reporting on the safety, pharmacokinetics, and efficacy of ADS051 in ulcerative colitis.